Large Molecule Pharmacokinetic Assays for New Modalities
Complete the form to view the recording.Share this resource:
Now Streaming On-Demand
PK assays are a vital component of the drug development process and the data derived is utilized to help select the dosage for preclinical and clinical studies. Large molecule PK bioanalytical assays are generally analyzed using LBAs. Therapeutic monoclonal antibodies and proteins are well-known drug modalities but recently, new modalities have entered the drug development scene. In this webinar, case studies from different drug modalities will be presented with a focus on assay setup and the challenges and solutions for validating the assay.
About the Presenter:
Marianne Scheel Fjording is a Scientific Officer at BioAgilytix. Marianne has an extensive background in large molecule bioanalytical assay set-up and assay validation. She has 20+ years of experience working in the pharmaceutical and biotechnology industry. Prior to joining BioAgilytix, she was Scientific Director at Novo Nordisk (Copenhagen, Denmark) where she delivered bioanalytical strategies for PK and biomarker assays.